Latest from The Tisch Cancer Institute

William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.
 

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.
 

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.
 

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.